Replies to post #44693 on Biotech Values

[genisi]

VRTX- " Piper Jaffray analyst Rachel McMinn wrote in a research note. "We view an SVR rate in the 40 percent to 50 percent range as more probable."

That's a lot lower than IDIX's board predictions:
http://www.investorshub.com/boards/read_msg.asp?message_id=15613926

[DewDiligence]

“We view the home run scenario of 75 percent SVR rate for telaprevir for only 12 weeks of therapy as possible but a long shot," Piper Jaffray analyst Rachel McMinn wrote in a research note. "We view an SVR rate in the 40 percent to 50 percent range as more probable.”

This is IMO an intellectually-dishonest attempt to lower expectations in order to pump the stock. Josh Boger himself has said that the SVR rate needed to establish 12 weeks of treatment as a new treatment standard is 85% (#msg-11635070).